CYPHERPUNK TECHNOLOGIES INC. Deferred Income Tax Expense (Benefit)
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Deferred Income Tax Expense (Benefit) of -$3.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-12
- CYPHERPUNK TECHNOLOGIES INC. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was $1.91M.
- CYPHERPUNK TECHNOLOGIES INC. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was -$5.12M.
- CYPHERPUNK TECHNOLOGIES INC. deferred income tax expense (benefit) for fiscal 2025 was $5.12M.
- CYPHERPUNK TECHNOLOGIES INC. deferred income tax expense (benefit) for fiscal 2022 was $147.00K, a 1030.77% increase from fiscal 2021.
- CYPHERPUNK TECHNOLOGIES INC. deferred income tax expense (benefit) for fiscal 2021 was $13.00K.
- CYPHERPUNK TECHNOLOGIES INC. deferred income tax expense (benefit) for fiscal 2020 was -$42.00K.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|
| 2026-06-30 | $1.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$3.21M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | -$5.12M 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $5.12M 10-K · filed 2026-03-16 | ||
| 2022-12-31 | $147.00K 10-K · filed 2024-03-18 | ||
| 2021-12-31 | $13.00K 10-K · filed 2023-03-24 | ||
| 2020-12-31 | -$42.00K 10-K · filed 2022-03-11 | ||
| 2019-12-31 | -$3.00K 10-K · filed 2021-03-12 | ||
| 2018-12-31 | $20.00K 10-K · filed 2020-03-16 | ||
| 2017-12-31 | -$157.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |